Omniox

About:

Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma.

Website: http://www.omniox.com

Twitter/X: Omniox

Top Investors: Plug and Play, Wellcome Trust, Samsara BioCapital, Casdin Capital, EcoR1 Capital

Description:

Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.

Total Funding Amount:

$20.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Carlos, California, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)omnioxinc.com

Founders:

Jonathan Winger, Stephen Cary

Number of Employees:

1-10

Last Funding Date:

2023-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai